+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Linagliptin"

From
From
From
From
From
From
From
Global Diabetes Care Drugs Market - Forecasts from 2022 to 2027 - Product Thumbnail Image

Global Diabetes Care Drugs Market - Forecasts from 2022 to 2027

  • Report
  • October 2022
  • 138 Pages
  • Global
From
Diabetes Care Drugs Market - Forecasts from 2020 to 2025 - Product Thumbnail Image

Diabetes Care Drugs Market - Forecasts from 2020 to 2025

  • Report
  • May 2020
  • 121 Pages
  • Global
From
Anti-Diabetic Drugs Market - Forecasts from 2020 to 2025 - Product Thumbnail Image

Anti-Diabetic Drugs Market - Forecasts from 2020 to 2025

  • Report
  • April 2020
  • 119 Pages
  • Global
From
Global and Chinese Linagliptin Industry, 2021 Market Research Report - Product Thumbnail Image

Global and Chinese Linagliptin Industry, 2021 Market Research Report

  • Report
  • January 2021
  • 149 Pages
  • China, Global
From
From
Loading Indicator

Linagliptin is a drug used to treat type 2 diabetes, a condition in which the body does not produce enough insulin or does not use insulin properly. It belongs to a class of drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors, which work by increasing the amount of insulin released by the pancreas. Linagliptin is used in combination with diet and exercise to improve glycemic control in adults with type 2 diabetes. It is also used to reduce the risk of cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Linagliptin is part of the Endocrine and Metabolic Disorders Drugs market, which includes drugs used to treat conditions such as diabetes, obesity, and thyroid disorders. These drugs are used to control blood sugar levels, reduce cholesterol, and regulate hormones. Companies in the Linagliptin market include Boehringer Ingelheim, Merck, Novartis, and Eli Lilly. Show Less Read more